OneSource Specialty Pharma
Stock Snapshot
Price Performance
Vista Outlook
Basis of our Recommendation
OneSource Specialty Pharma is transitioning into a high-growth phase, driven by its leadership in the generic semaglutide market and aggressive expansion of its biologics infrastructure. Management's confidence is bolstered by a robust order book and a strategic focus on high-margin CDMO services, which are expected to enhance revenue growth and margins. However, execution risks related to capacity upgrades and regulatory compliance remain pertinent. Vista's financial outlook anticipates a recovery in revenue growth, with margins improving as operational efficiencies are realized. The company's valuation reflects expectations of sustained long-term growth, despite current cautious investor sentiment. Industry dynamics, including improving pricing power and the shift towards Indian CDMOs, support this outlook, although challenges such as raw material supply constraints and regulatory impacts could pose risks. Over the next 12-24 months, key opportunities include scaling GLP-1 product supplies and diversifying into biologics, while watchpoints include execution risks from capacity expansions and potential pricing pressures in a competitive landscape
Why We Like This Stock
- Strong leadership in the generic semaglutide market positions OneSource for significant revenue growth
- Aggressive expansion of biologics infrastructure is expected to enhance margins and long-term growth potential
- A robust order book and strategic focus on high-margin CDMO services support Vista's positive financial outlook
Things To Watch Out For
- Execution risks associated with major capacity upgrades and regulatory compliance could impact operational performance
- Cautious investor sentiment reflects concerns over the company's ability to convert its order book into realized sales
- Potential pricing pressures in a competitive landscape may challenge margin expansion efforts
Key Parameters
Financial Snapshot
View Technicals Analysis →| Actuals | Forecast | ||||
|---|---|---|---|---|---|
| FY24 | FY25 | FY26 | FY27 | FY28 | |
| Revenue (Cr.) | 172 | 1,445 | 1,422 | 1,466 | 1,845 |
| Profit Before Tax (Cr.) | -244 | 44 | -82 | -81 | 7 |
| PBT Margin | -141.9% | 3.0% | -5.8% | -5.5% | 0.4% |
| Net Profit (Cr.) | -269 | 99 | -84 | -60 | 5 |
| Earnings Per Share | -23.5 | 8.6 | -7.4 | -5.3 | 0.4 |
Analyst Recommendations
| Broker | Recommendation | Target Price | Date |
|---|---|---|---|
| ICICI Securities | ▲ Buy | 2,400 | 07-Sep-2026 |
Company Overview
Show Company Profile
OneSource Specialty Pharma Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of biological drug products in various injectable formats in India, Ireland, the United States, and internationally. The company provides end-to-end contract development and manufacturing operations (CDMO) services across various phases of preclinical and clinical development and commercial supply of biologics. It also offers drug-devices, including prefilled syringes, dial and push variable and fixed dose pen injectors, pull push fixed dose pens, and autoinjectors; sterile injectables; soft gelatin capsules; and biologics solutions for microbial and mammalian cell line biopharmaceuticals, cell and gene therapy, and RNA products. The company was formerly known as Stelis Biopharma Limited and changed its name to OneSource Specialty Pharma Limited in February 2024. OneSource Specialty Pharma Limited was incorporated in 2007 and is based in Bengaluru, India.